Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults.
Monika Tomaszewska-KiecanaMartin UllmannCorinne Petit-FrereJoëlle MonnetChristos DagresAndras IllesPublished in: Expert review of clinical immunology (2023)
The trial is registered at EudraCT, number 2019-003484-22.